C677T polymorphism of the methylenetetrahydrofolate reductase gene is a risk factor of adverse events after coronary revascularization

International Journal of Cardiology

Volumn 96, Issue 3, 2004, Pages 341-345

  Botto, Nicoletta ^a,b   Andreassi, Maria Grazia ^a   Rizza, Antonio ^a   Berti, Sergio ^a   Bevilacqua, Stefano ^a   Federici, Chiara ^a   Palmieri, Cataldo ^a   Glauber, Mattia ^a   Biagini, Andrea ^a  

^a G PASQUINUCCI HOSPITAL   (Italy)

^b Sant' Anna Sch Univ Studs D   (Italy)

Author keywords

Coronary artery bypass graft; Coronary artery disease; Follow up; Homocysteine; MTHFR genotype; Percutaneous transluminal coronary angioplasty

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC RISK; GENOTYPE; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; FEMALE; FOLLOW-UP STUDIES; HEART DISEASES; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; RECURRENCE; RISK FACTORS; TREATMENT FAILURE;

EID: 4143111407     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.06.022     Document Type: Article

References (43)

1. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324:1991;1149-1155
2. Fonseca V., Guba S.C., Fink L.M. Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr. Rev. 20:1999;738-759
3. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337:1997;230-236
4. Anderson J.L., Muhlestein J.B., Horne B.D., et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 102:2000;1227-1232
5. Morita H., Kurihara H., Kuwaki T., et al. Homocysteine as a risk factor for restenosis after coronary angioplasty. Thromb. Haemost. 84:2000;27-31
6. Kumbasar S.D., Dincer I., Ertasetal F., et al. Hyperhomocysteinemia and restenosis. J. Cardiovasc. Risk. 8:2001;9-13
7. Schnyder G., Roffi M., Flammer Y., Pin R., Hess O.M. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur. Heart J. 23:2002;726-733
8. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113
9. Jacques P.F., Bostom A.G., Williams R.R., et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9
10. Christensen B., Frosst P., Lussier-Cacan S., et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 17:1997;569-573
11. Kluijtmans L.A., Kastelein J.J., Lindemans J., et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 96:1997;2573-2577
12. Gallagher P.M., Meleady R., Shields D.C., et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation. 94:1996;2154-2158
13. Ma J., Stampfer M.J., Hennekens C.H., et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416
14. Schmitz C., Lindpaintner K., Verhoef P., Gaziano J.M., Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation. 94:1996;1812-1814
15. Morita H., Taguchi J., Kurihara H., et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 95:1997;2032-2036
16. Brattstrom L., Wilcken D.E., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 98:1998;2520-2526
17. Reinhardt D., Sigusch H.H., Vogt S.F., Farker K., Muller S., Hoffmann A. Absence of association between a common mutation in the methylenetetrahydrofolate reductase gene and the risk of coronary artery disease. Eur. J. Clin. Invest. 28:1998;20-23
18. Payne D.A., Chamoun A.J., Seifert S.L., Stouffer G.A. MTHFR 677 C→T mutation: a predictor of early-onset coronary artery disease risk. Thromb. Res. 103:2001;275-279
19. Mager A., Battler A., Birnbaum Y., Magal N., Shohat M. Plasma homocysteine methylenetetrahydrofolate reductase genotypes and age at onset of symptoms of myocardial ischemia. Am. J. Cardiol. 89:2002;919-923
20. Kosokabe T., Okumura K., Sone T., et al. Relation of a common methylenetetrahydrofolate reductase mutation and plasma homocysteine with intimal hyperplasia after coronary stenting. Circulation. 103:2001;2048-2054
21. Miner S.E., Hegele R.A., Sparkes J., et al. Homocysteine, lipoprotein(a), and restenosis after percutaneous transluminal coronary angioplasty: a prospective study. Am. Heart J. 140:2000;272-278
22. Abbate R., Sardi I., Pepe G., et al. The high prevalence of thermolabile 5,10-methylenetetrahydrofolate reductase (MTHFR) in Italians is not associated to an increased risk for coronary artery disease (CAD). Thromb. Haemost. 79:1998;727-730
23. Smith L.R., Harrel F.E., Rankin J.S., et al. Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. Circulation. 84(Suppl. III):1991;III245-III253
24. Bostom A.G., Silbershatz H., Rosenberg I.H., et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch. Intern. Med. 159:1999;1077-1080
25. Kark J.D., Selhub J., Bostom A., Adler B., Rosenberg I.H. Plasma homocysteine and all-cause mortality in diabetes. Lancet. 353:1999;1936-1937
26. Vollset S.E., Refsum H., Tverdal A., et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland homocysteine study. Am. J. Clin. Nutr. 74:2001;130-136
27. Schnyder G., Roffi M., Pin R., et al. Decrease rate of coronary restenosis after lowering of plasma homocysteine levels. N. Engl. J. Med. 345:2001;1593-1600
28. Morita H., Kurihara H., Yoshida S., et al. Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. Circulation. 103:2001;133-139
29. Southern F., Eidt J., Drouilhet J., et al. Increasing levels of dietary homocysteine with carotid endarterectomy produced proportionate increases in plasma homocysteine and intimal hyperplasia. Atherosclerosis. 158:2001;129-138
30. Eikelboom J.W., Lonn E., Genest J. Jr., Hankey G., Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. 131:1999;363-375
31. Thambyrajah J., Townend J.N. Homocysteine and atherothrombosis - mechanisms for injury. Eur. Heart J. 21:2000;967-974
32. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J. Clin. Invest. 98:1996;5-7
33. Fenech M. The role of folic acid and vitamin B12 in genomic stability of human cells. Mutat. Res. 475:2001;57-67
34. Yi P., Melnyk S., Pogribna M., Pogribny I.P., Hine R.J., James S.J. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosylhomocysteine and lymphocyte DNA hypomethylation. J. Biol. Chem. 275:2000;29318-29323
35. Chen Z., Karaplis A.C., Ackerman S.L., et al. Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet. 10:2001;433-443
36. Stern L.L., Mason J.B., Selhub J., Choi S.W. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol. Biomarkers Prev. 9:2000;849-853
37. Friso S., Choi S.W., Girelli D., et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl. Acad. Sci. U. S. A. 99:2002;5606-56011
38. Andreassi M.G., Botto N., Colombo M.G., Biagini A., Clerico A. Genetic instability and atherosclerosis: can somatic mutations account for the development of cardiovascular diseases? Environ. Mol. Mutagen. 35:2000;265-269
39. Andreassi M.G. Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutat. Res. 543:2003;67-86
40. Bennett M.R. Reactive oxygen species and death: oxidative DNA damage in atherosclerosis. Circ. Res. 88:2001;648-650
41. Andreassi M.G., Botto N., Rizza A., et al. Deoxyribonucleic acid damage in human lymphocytes after percutaneous transluminal coronary angioplasty. JACC. 40:2002;862-868
42. Andreassi M.G., Botto N., Cocci F., et al. Methylentetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. Hum. Genet. 112:2003;171-177
43. Kibbe M.R., Hasset A.L., McSherry F., et al. Can screening for genetic markers improve peripheral artery bypass patency? J. Vasc. Surg. 36:2002;1198-1206